Hims & Hers announced a significant step in its global expansion through its agreement to acquire Zava. This strategic move will expand Hims & Hers’ footprint in the United Kingdom and will officially launch the company into Germany, France, and Ireland, with more markets anticipated soon. Hims & Hers will establish its own branded presence, leveraging the robust Zava platform, in each of these European markets in the coming quarters. The acquisition consideration will be comprised of 100% cash, to be funded from the company’s balance sheet at closing. The acquisition is expected to close in the second half of 2025, and Hims & Hers expects to continue expanding globally as demand for personalized healthcare continues to grow.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Hims & Hers (HIMS) Lays Off 4% of Workforce Post Ban on Weight-Loss Drug Copies
- Hims & Hers to cut 68 employees, or 4% of workforce, Reuters reports
- LifeMD price target raised to $15 from $12 at BTIG
- Mixed options sentiment in Hims and Hers Health with shares up 2.0%
- Why Hims & Hers Health Stock (HIMS) Is Too Hot to Handle